559 related articles for article (PubMed ID: 9815772)
1. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
2. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
Frost P; Ng CP; Belldegrun A; Bonavida B
Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
5. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
Borsellino N; Belldegrun A; Bonavida B
Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
[TBL] [Abstract][Full Text] [Related]
6. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
7. Fas-mediated apoptosis in human prostatic carcinoma cell lines.
Rokhlin OW; Bishop GA; Hostager BS; Waldschmidt TJ; Sidorenko SP; Pavloff N; Kiefer MC; Umansky SR; Glover RA; Cohen MB
Cancer Res; 1997 May; 57(9):1758-68. PubMed ID: 9135020
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
[TBL] [Abstract][Full Text] [Related]
9. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
Frost PJ; Belldegrun A; Bonavida B
Prostate; 1999 Sep; 41(1):20-30. PubMed ID: 10440872
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
[TBL] [Abstract][Full Text] [Related]
12. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
Sun SY; Yue P; Lotan R
Oncogene; 2000 Sep; 19(39):4513-22. PubMed ID: 11002424
[TBL] [Abstract][Full Text] [Related]
13. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins.
Morimoto H; Yonehara S; Bonavida B
Cancer Res; 1993 Jun; 53(11):2591-6. PubMed ID: 7684321
[TBL] [Abstract][Full Text] [Related]
14. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
Ando K; Hiroishi K; Kaneko T; Moriyama T; Muto Y; Kayagaki N; Yagita H; Okumura K; Imawari M
J Immunol; 1997 Jun; 158(11):5283-91. PubMed ID: 9164947
[TBL] [Abstract][Full Text] [Related]
15. Fas (CD95, APO-1) antigen expression and function in murine mast cells.
Hartmann K; Wagelie-Steffen AL; von Stebut E; Metcalfe DD
J Immunol; 1997 Oct; 159(8):4006-14. PubMed ID: 9378990
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
[TBL] [Abstract][Full Text] [Related]
17. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
Huerta-Yepez S; Vega M; Garban H; Bonavida B
Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
[TBL] [Abstract][Full Text] [Related]
19. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.
Oshimi Y; Oda S; Honda Y; Nagata S; Miyazaki S
J Immunol; 1996 Oct; 157(7):2909-15. PubMed ID: 8816396
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
Chatterjee D; Schmitz I; Krueger A; Yeung K; Kirchhoff S; Krammer PH; Peter ME; Wyche JH; Pantazis P
Cancer Res; 2001 Oct; 61(19):7148-54. PubMed ID: 11585748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
